Liquidia Corporation (LQDA) Financial Ratios
9 years of historical data (2016–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
43.06
↑+468% vs avg
5yr avg: 7.58
30Y Low1.4·High16.5
ROE
↓
-209.4%
↑-94% vs avg
5yr avg: -107.9%
30Y Low-284%·High-51%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
LQDA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Liquidia Corporation currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.7B | $926M | $782M | $388M | $242M | $100M | $79M | $155M | — | — |
| Enterprise Value | $3.6B | $872M | $748M | $319M | $201M | $52M | $48M | $128M | — | — |
| P/E Ratio → | -25.47 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 262.27 | 66.13 | 44.71 | 24.37 | 18.82 | 135.16 | 9.79 | 57.32 | — | — |
| P/B Ratio | 43.06 | 11.98 | 16.53 | 4.29 | 3.71 | 1.41 | 2.26 | 8.30 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
LQDA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 62.27 | 42.76 | 20.05 | 15.60 | 70.03 | 5.90 | 47.43 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
LQDA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Liquidia Corporation earns an operating margin of -866.6%. Operating margins have compressed from -243.3% to -866.6% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -209.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 58.0% | 58.0% | 83.5% | 82.1% | 76.5% | 67.9% | 90.0% | 95.5% | 95.6% | 93.0% |
| Operating Margin | -866.6% | -866.6% | -419.6% | -243.3% | -263.0% | -7989.0% | -580.1% | -1288.1% | -386.2% | -120.0% |
| Net Profit Margin | -931.7% | -931.7% | -448.9% | -257.4% | -269.0% | -8080.1% | -589.5% | -1962.9% | -401.7% | -120.6% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -209.4% | -209.4% | -114.0% | -52.7% | -50.7% | -112.7% | -177.4% | -284.3% | — | — |
| ROA | -74.8% | -74.8% | -63.4% | -36.8% | -35.8% | -71.0% | -80.5% | -165.4% | -249.9% | -187.8% |
| ROIC | -500.7% | -500.7% | -316.7% | -127.9% | -108.4% | -334.7% | — | — | — | — |
| ROCE | -84.1% | -84.1% | -66.7% | -37.5% | -38.8% | -84.6% | -100.5% | -273.6% | — | — |
LQDA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $176M exceeds total debt of $122M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.58 | 1.58 | 1.05 | 0.27 | 0.25 | 0.24 | 0.70 | 0.68 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.70 | -0.72 | -0.76 | -0.63 | -0.68 | -0.90 | -1.43 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -9.71 | -9.71 | -11.70 | -16.58 | -44.35 | -68.87 | -34.09 | -1.84 | -2.15 | -184.74 |
Net cash position: cash ($176M) exceeds total debt ($122M)
LQDA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Liquidia Corporation's current ratio of 4.43x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 11.34x to 4.43x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.43 | 4.43 | 4.85 | 11.34 | 8.36 | 5.63 | 3.34 | 4.85 | 0.18 | 0.26 |
| Quick Ratio | 4.42 | 4.42 | 4.85 | 11.34 | 8.36 | 5.63 | 3.34 | 4.85 | 0.18 | 0.26 |
| Cash Ratio | 4.22 | 4.22 | 4.51 | 10.60 | 7.85 | 5.56 | 3.31 | 4.79 | 0.11 | 0.12 |
| Asset Turnover | — | 0.06 | 0.15 | 0.12 | 0.14 | 0.01 | 0.12 | 0.05 | 0.49 | 1.56 |
| Inventory Turnover | 24.39 | 24.39 | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 70.91 | 84.76 | 114.92 | 84.91 | — | — | 36.75 | 81.58 | 34.21 |
LQDA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Liquidia Corporation does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $79M | $65M | $61M | $50M | $34M | $18M | $7M | $9M | $9M |
Peer Comparison
Compare LQDA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 LQDAYou | $4B | -25.5 | — | — | 58.0% | -866.6% | -209.4% | -500.7% | — |
 UTHR | $25B | 20.4 | 14.8 | 24.0 | 87.9% | 46.9% | 19.7% | 21.1% | — |
 MNKD | $1B | 177.5 | 29.3 | 80.1 | 82.5% | 11.1% | — | 21.6% | 9.3 |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 INSM | $23B | -16.3 | — | — | 79.4% | -194.0% | -249.3% | -86.5% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 PBYI | $369M | 11.9 | 7.6 | 8.9 | 74.5% | 16.3% | 28.0% | 24.7% | 0.6 |
 KALA | $617676 | -0.0 | — | — | — | — | -388.3% | — | — |
 JNJ | $536B | 38.4 | 18.6 | 27.0 | 69.1% | 24.9% | 20.1% | 20.7% | 1.2 |
 MRK | $277B | 15.4 | 10.7 | 22.4 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
See LQDA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LQDA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LQDA vs UTHR
Side-by-side business, growth, and profitability comparison vs United Therapeutics Corporation.
Start ComparisonLQDA — Frequently Asked Questions
Quick answers to the most common questions about buying LQDA stock.
What is Liquidia Corporation's P/E ratio?
Liquidia Corporation's current P/E ratio is -25.5x. This places it at the 50th percentile of its historical range.
What is Liquidia Corporation's ROE?
Liquidia Corporation's return on equity (ROE) is -209.4%. The historical average is -143.0%.
Is LQDA stock overvalued?
Based on historical data, Liquidia Corporation is trading at a P/E of -25.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Liquidia Corporation's profit margins?
Liquidia Corporation has 58.0% gross margin and -866.6% operating margin.